Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy

High platelet reactivity (HPR) on clopidogrel is an established thrombotic risk factor after percutaneous coronary intervention (PCI). The introduction of more potent antiplatelet drugs has partially surpassed this issue. However, in the setting of concomitant atrial fibrillation (AF) and PCI clopid...

Descripción completa

Detalles Bibliográficos
Autores principales: Berteotti, M., Gori, A. M., Giusti, B., Fortini, A., Grossi, G., Ciardetti, N., Migliorini, A., Lotti, E., Valenti, R., Di Mario, C., Marchionni, N., Marcucci, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147742/
https://www.ncbi.nlm.nih.gov/pubmed/36905562
http://dx.doi.org/10.1007/s11239-023-02784-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147742/
https://www.ncbi.nlm.nih.gov/pubmed/36905562
http://dx.doi.org/10.1007/s11239-023-02784-z

Ejemplares similares